Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Haematology

Topics

Medicine

Immunology

Pathology

Internal Medicine

Hematology

Show all topics

DOI

10.1016/s2352-3026(24)00139-x